GRMN
43
3
XEL
60
-9
PSA
50
-5
JBHT
35
2
MLM
51
-2
AA
50
-3
MPC
42
-2
HST
29
-3
PDCO
69
-2
IRM
44
-2
FLS
57
-2
RHI
23
-2
L
60
8
FMC
31
-3
VIX
44
-3
AZO
53
-9
CAG
53
-2
MOS
53
-5
UHS
59
-4
AON
73
-2
GRMN
43
3
XEL
60
-9
PSA
50
-5
JBHT
35
2
MLM
51
-2
AA
50
-3
MPC
42
-2
HST
29
-3
PDCO
69
-2
IRM
44
-2
FLS
57
-2
RHI
23
-2
L
60
8
FMC
31
-3
VIX
44
-3
AZO
53
-9
CAG
53
-2
MOS
53
-5
UHS
59
-4
AON
73
-2
Financhill
Back

Zevra Therapeutics 10K Form

Sell
37

ZVRA
Zevra Therapeutics

Last Price:
$8.00
Seasonality Move:
-11.97%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ZVRA News And Ratings

See the #1 stock for the next 7 days that we like better than ZVRA

ZVRA Financial Statistics

Sales & Book Value

Annual Sales: $23.6M
Cash Flow: $-16.3M
Price / Cash Flow: 0
Annual Sales: $0.74
Price / Book: 10.93

Profitability

EPS (TTM): -2.26000
Net Income (TTM): $-105.5M
Gross Margin: $16.2M
Return on Equity: -208.85%
Return on Assets: -62.98%

Zevra Therapeutics Earnings Forecast

Key Zevra Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 12 years for ZVRA is 68.59%.
  • The Selling, General & Administrative Expenses for ZVRA have been equal to 232.37% of Gross Profit Margin.
  • The Research & Development expenses have been 178.28% of Revenue.
  • The Net Earning history of ZVRA is -446.85% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 5 years.

Zevra Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ZVRA
Website: zevra.com

Debt

Debt-to-Equity Ratio: 1.5
Current Ratio: 2.53
Quick Ratio: 2.35

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 12.27

ZVRA Technical Analysis vs Fundamental Analysis

Sell
37
Zevra Therapeutics (ZVRA) is a Sell

Is Zevra Therapeutics a Buy or a Sell?